Eisbach Bio

Executive Summary

Eisbach Bio is a clinical-stage biotechnology company based in Munich, Germany, founded in 2019. The company focuses on developing next-generation small-molecule cancer therapies by targeting genetically defined vulnerabilities in tumors. Its proprietary ALLOS platform integrates AI-guided molecular design to discover allosteric inhibitors of key molecular machines involved in cancer, such as chromatin remodelers and transcription factors. This approach aims to achieve high selectivity and reduced off-target toxicity compared to conventional inhibitors. Eisbach Bio has advanced its lead program into Phase 2 clinical trials, targeting a specific genetic alteration prevalent in certain solid tumors. The company's AI-driven discovery engine continues to generate a pipeline of novel allosteric inhibitors, positioning it to address multiple oncology indications with high unmet medical need. As a private company, Eisbach Bio has attracted interest from specialized healthcare investors, though specific funding details are not publicly disclosed. The company's strategic location in Munich benefits from Germany's strong biotech ecosystem and proximity to leading academic research institutions.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead allosteric inhibitor program40% success
• Q4 2026Partnership or licensing deal for ALLOS platform30% success
• Q1 2027IND filing for next preclinical candidate60% success